Guardant Health Inc

GHNASDAQ · USD
151.70USD0.00 (-2.05%)
2410

Guardant Health Inc (GH) Covered Calls

Guardant Health Inc trades in the Diagnostics & Research industry with an IV Rank of 25.79%, low versus the past year. GH's highest covered call setup is the $180.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 18.66% out of the money with 7 days to expiration, a 18.69% return until expiration, and a 974.46% theoretical annualized return. Across the setups shown, annualized returns run from 189.24% to 974.46% at strikes between $160.00 and $250.00, with 7 to 126 days to expiration, as of Nov 13, 2026.

Read more

Running GH covered calls helps you generate income from Guardant Health Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GH covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If GH stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GH covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GH covered call is worth writing.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.

2026-11-207180.0018.660.051.852835.0018.69974.46-0.03+0.111451.80
2026-11-207175.0015.360.051.352335.0015.39802.59-0.03+0.101561.30
2026-12-1835200.0031.840.103.804840.0031.91332.72-0.07+0.13153.70
2026-12-1835195.0028.540.103.804340.0028.61298.35-0.07+0.14213.70
2026-11-207160.005.470.104.40840.005.54288.73-0.07+0.293404.30
2027-01-1563220.0045.020.303.906860.0045.22261.99-0.20+0.122963.60
2026-12-1835185.0021.950.103.303340.0022.02229.61-0.07+0.143243.20
2027-01-1563210.0038.430.404.205870.0038.69224.18-0.26+0.131513.80
2026-12-1835180.0018.661.004.302930.0019.31201.42-0.66+0.19333.30
2027-03-19126250.0064.800.804.509910.0065.33189.24-0.53+0.121603.70

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDiagnostics & Research
  • SectorHealthcare
  • IV Rank25.79% Low
  • Market cap (M$)20,523
  • 52 weeks high-20.60%
  • 52 weeks low103.49%
  • Analyst recommendationStrong Buy
    1.41
  • Target price$204.75
    34.97% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.68
  • EPS growth next 5 years53.72%

As of Nov 13, 2026